View Our Abstracts at the 2024 ASCO® Annual Meeting
In-Person Poster Presentation
June 1, 2024
1:30 PM to 4:30 PM CDT
Abstract Number: 4110
Title: Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.
Abstract Number: e16197
Title: Role of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte-ratio (PLR) in unresectable hepatocellular carcinoma (uHCC): Subgroup analysis of patients treated with camrelizumab (cam) + rivoceranib (rivo) in the CARES-310 trial.
View the Complementary MOAs of Camrelizumab + Rivoceranib
Camrelizumab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor.1
Rivoceranib is a small-molecule tyrosine kinase inhibitor (TKI) that works to inhibit the vascular endothelial growth factor receptor (VEGFR), a primary pathway for tumor angiogenesis.1,2
WHAT ELSE IS HAPPENING IN THE BOOTH?
Experience the “TKI Selectivity Match-up”
In this interactive touchscreen display, you can compare the selectivity of TKIs and see how others measure up to rivoceranib.
Review the latest uHCC data
Talk to a team member in the booth about what’s new in uHCC treatment.
Stay connected
Sign up to receive important information about camrelizumab + rivoceranib, company news, and updates or to connect with a member of our team.
*Required field
References: 1. Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402(10408):1133-1146. 2. Jang S, Strickland B, Finis L, et al. Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor. Cancer Chemother Pharmacol. 2023;91(6):491-499.
